{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:58:10Z","timestamp":1790182690375,"version":"4.1.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,8,6]],"date-time":"2013-08-06T00:00:00Z","timestamp":1375747200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s40259-013-0057-y","type":"journal-article","created":{"date-parts":[[2013,8,5]],"date-time":"2013-08-05T11:48:36Z","timestamp":1375703316000},"page":"509-523","source":"Crossref","is-referenced-by-count":21,"title":["Lixisenatide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus"],"prefix":"10.1007","volume":"27","author":[{"given":"Lesley J.","family":"Scott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,6]]},"reference":[{"key":"57_CR1","unstructured":"International Diabetes Federation. Global diabetes plan 2011\u20132021; 2012. http:\/\/www.idf.org\/sites\/default\/files\/Global_Diabetes_Plan_Final.pdf (Accessed 6 May 2013)."},{"key":"57_CR2","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","volume":"35","author":"SE Inzucchi","year":"2012","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes. Diabetes Care. 2012;35:1364\u201379.","journal-title":"Diabetes Care"},{"issue":"12","key":"57_CR3","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1210\/jc.2012-3487","volume":"97","author":"R Sherwin","year":"2012","unstructured":"Sherwin R, Jastreboff AM. Year in diabetes 2012: the diabetes tsunami. J Clin Endocrinol Metab. 2012;97(12):4293\u2013301.","journal-title":"J Clin Endocrinol Metab"},{"key":"57_CR4","doi-asserted-by":"crossref","unstructured":"Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med. 2011;124 Suppl.:S3\u201318.","DOI":"10.1016\/j.amjmed.2010.11.002"},{"key":"57_CR5","doi-asserted-by":"crossref","unstructured":"Nauck MA. Unraveling the science of incretin biology. Am J Med. 2009;122 Suppl.:S3\u201310.","DOI":"10.1016\/j.amjmed.2009.03.012"},{"key":"57_CR6","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696\u2013705.","journal-title":"Lancet"},{"issue":"11","key":"57_CR7","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1124\/dmd.110.034066","volume":"38","author":"M Malm-Erjefalt","year":"2010","unstructured":"Malm-Erjefalt M, Bjornsdottir I, Vanggaard J, et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos. 2010;38(11):1944\u201353.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"57_CR8","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2337\/dc11-1935","volume":"35","author":"VA Fonseca","year":"2012","unstructured":"Fonseca VA, Alvarado-Ruiz R, Raccah D, et al. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care. 2012;35(6):1225\u201331.","journal-title":"Diabetes Care"},{"issue":"2","key":"57_CR9","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1124\/jpet.103.051987","volume":"302","author":"C Thorkildsen","year":"2003","unstructured":"Thorkildsen C, Neve S, Larsen BD, et al. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db\/db mice. J Pharmacol Exp Ther. 2003;302(2):490\u20136.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2\u20133","key":"57_CR10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.regpep.2010.05.008","volume":"164","author":"U Werner","year":"2010","unstructured":"Werner U, Haschke G, Herling AW, et al. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept. 2010;164(2\u20133):58\u201364.","journal-title":"Regul Pept"},{"issue":"2","key":"57_CR11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s12325-013-0009-4","volume":"30","author":"M Horowitz","year":"2013","unstructured":"Horowitz M, Rayner CK, Jones KL. Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes. Adv Ther. 2013;30(2):81\u2013101.","journal-title":"Adv Ther"},{"key":"57_CR12","unstructured":"Werner U, Gerlach M, Hofmann M, et al. Combination of lixisenatide and insulin glargine demonstrates complementary pharmacological activity on glycemic control in animal models of diabetes [abstract no.1051-p]. Diabetes. 2012;61 Suppl.1:A270."},{"key":"57_CR13","unstructured":"European Medicines Agency. Lixisenatide: summary of product characteristics; 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002445\/WC500140401.pdf (Accessed 8 Apr 2013)."},{"issue":"7","key":"57_CR14","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/dom.12076","volume":"15","author":"C Kapitza","year":"2013","unstructured":"Kapitza C, Forst T, Coester H-V, et al. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes inadequately controlled on metformin. Diabetes Obes Metabol. 2013;15(7):642\u20139.","journal-title":"Diabetes Obes Metabol"},{"key":"57_CR15","unstructured":"Becker RH, Kapitza C, Stechl J, et al. Restitution of glucose disposition with lixisenatide in subjects with type 2 diabetes [abstract no.813]. Diabetologia. 2012;55 Suppl.1:S335\u2013S6."},{"key":"57_CR16","unstructured":"Becker RHA, Ruus P, Li YH, et al. Restoration of insulin release with lixisenatide in patients with type 2 diabetes [abstract no. 850]. Diabetologia. 2010;53 Suppl.1:S339."},{"key":"57_CR17","first-page":"S336","volume":"55","author":"J Stechl","year":"2012","unstructured":"Stechl J, Becker RH, Kapitza C, et al. Augmentation of first-phase insulin release with lixisenatide in nondiabetic subjects [abstract no. 814]. Diabetologia. 2012;55:S336.","journal-title":"Diabetologia"},{"key":"57_CR18","unstructured":"Ratner RE, Hanefeld M, Shamanna P, et al. Post-meal pharmacodynamic profile of lixisenatide once daily vs placebo in T2DM insufficiently controlled on SU\u00a0\u00b1\u00a0metformin (GetGoal-S) [abstract no. D-0743]. 21st World Congress of the International Diabetes Federation, Dubai; 4\u20138 Dec 2011."},{"key":"57_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.regpep.2013.04.001","volume":"185C","author":"M Lorenz","year":"2013","unstructured":"Lorenz M, Pfeiffer C, Steinstraser A, et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes: relationship to postprandial glycemia. Regul Peptides. 2013;185C:1\u20138.","journal-title":"Regul Peptides"},{"key":"57_CR20","unstructured":"Hubschle T, Schafer HL, Juretschke HP, et al. Anti-atherosclerotic activity of lixisenatide in ApoE knockout mice [abstract no. 809]. Diabetologia. 2012;55 Suppl.1:S334."},{"key":"57_CR21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1479-5876-11-84","volume":"11","author":"P Wohlfart","year":"2013","unstructured":"Wohlfart P, Linz W, Hubschle T, et al. Cardioprotective effects of lixisenatide in rat myocardial ischaemia-reperfusion injury studies. J Transl Med. 2013;11:84.","journal-title":"J Transl Med"},{"key":"57_CR22","unstructured":"Liu Y-H, Ruus P. Effect of GLP-1 receptor agonist AVE0010 on the absorption of concomitant oral drugs: acetaminophen and ethinylestradiol\/levonorgestrel [abstract no. 776]. 45th Annual Meeting of the European Association for the Study of Diabetes, Vienna; 29 Sep\u20132 Oct 2009."},{"key":"57_CR23","unstructured":"Liu YH, Ruus P, Steinstraesser A, et al. Effect of the GLP-1 agonist lixisenatide on the pharmacokinetics of warfarin [abstract no. 2128-PO]. 70th Annual Scientific Sessions of the American Diabetes Association, Orlando; 25\u201329 Jun 2010."},{"key":"57_CR24","unstructured":"Dahmen R, Steinstraesser A, Poitiers F, et al. Interaction of subcutaneous lixisenatide 20\u00a0\u03bcg QD on pharmacokinetic and pharmacodynamic properties of oral ramipril 5\u00a0mg QD [abstract]. Basic Clin Pharmacol Toxicol. 2011;109 Suppl.:89."},{"issue":"Suppl. 1","key":"57_CR25","first-page":"S316","volume":"54","author":"G Bolli","year":"2011","unstructured":"Bolli G, Munteanu M, Dotsenko S, et al. Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on metformin (GetGoal-F1) [abstract no. 784]. Diabetologia. 2011;54(Suppl. 1):S316\u20137.","journal-title":"Diabetologia"},{"key":"57_CR26","author":"B Ahren","year":"2013","unstructured":"Ahren B, Leguizamo A, Miossec P, et al. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care. 2013. doi: 10.2337\/dc12-2006 .","journal-title":"Diabetes Care"},{"key":"57_CR27","unstructured":"Pan CY, Zhao Q, Niemoeller E. Lixisenatide in Asian patients with type 2 diabetes (T2DM) uncontrolled on metformin\u00a0\u00b1\u00a0sulfonylurea (SU): GetGoal-M Asia [abstract no. PCS-20-3]. J Diabetes Invest. 2012;3 Suppl.1:204."},{"key":"57_CR28","unstructured":"Ratner RE, Hanefeld M, Shamanna P, et al. Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on sulfonylurea\u00a0\u00b1\u00a0metformin (GetGoal-S) [abstract no. 785]. Diabetologia. 2011;54 Suppl.1:S317."},{"key":"57_CR29","doi-asserted-by":"crossref","unstructured":"Pinget M, Goldenberg R, Niemoeller E, et al. Efficacy and safety of lixisenatide once daily versus placebo in patients with type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes Obes Metab. 2013. doi: 10.1111\/dom.12121 .","DOI":"10.1111\/dom.12121"},{"key":"57_CR30","author":"MC Riddle","year":"2013","unstructured":"Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care. 2013. doi: 10.2337\/dc12-2454 .","journal-title":"Diabetes Care"},{"issue":"10","key":"57_CR31","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1463-1326.2012.01618.x","volume":"14","author":"Y Seino","year":"2012","unstructured":"Seino Y, Min KW, Niemoeller E, et al. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab. 2012;14(10):910\u20137.","journal-title":"Diabetes Obes Metab"},{"key":"57_CR32","author":"MC Riddle","year":"2013","unstructured":"Riddle MC, Forst T, Aronson R, et al. Adding once-daily lixisenatide in type 2 diabetes inadequately controlled with newly initiated insulin and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-DUO-l). Diabetes Care. 2013. doi: 10.2337\/dc12-2462 .","journal-title":"Diabetes Care"},{"key":"57_CR33","author":"J Rosenstock","year":"2013","unstructured":"Rosenstock J, Raccah D, Koranyi L, et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care. 2013. doi: 10.2337\/dc12-2709 .","journal-title":"Diabetes Care"},{"key":"57_CR34","unstructured":"European Medicines Agency. Assessment report Lyxumia. 2012. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002445\/WC500140449.pdf (Accessed 8 Apr 2013)."},{"key":"57_CR35","unstructured":"Sanofi. 24-week study comparing lixisenatide (AVE0010) to sitagliptin as add-on to metformin in obese type 2 diabetic patients younger than 50 [ClinicalTrials.gov identifier NCT00976937]. US National Institutes of Health, ClinicalTrials.gov; 2012. http:\/\/www.clinicaltrials.gov (Accessed 9 April 2013)."},{"key":"57_CR36","unstructured":"Sanofi. GLP-1 agonist AVE0010 in patients with type 2 diabetes for gylcemic control and safety evaluation, on top of sulfonylurea (GetGoal-S) [ClinicalTrials.gov identifier NCT00713830]. US National Institutes of Health, ClinicalTrials.gov; 2012. http:\/\/www.clinicaltrials.gov (Accessed 12 Apr 2013)."},{"key":"57_CR37","unstructured":"Sanofi. Efficacy and safety of lixisenatide in patients with type 2 diabetes mellitus insufficiently controlled by metformin (GetGoal-M-Asia) [ClinicalTrials.gov identifier NCT01169779]. US National Institutes of Health, ClinicalTrials.gov; 2012. http:\/\/www.clinicaltrials.gov (Accessed 12 Apr 2013)."},{"key":"57_CR38","unstructured":"Sanofi. GLP-1 agonist AVE0010 in patients with type 2 diabetes for gylcemic control and safety evaluation, on top of metformin (GetGoal-F1) [ClinicalTrials.gov identifier NCT00763451]. US National Institutes of Health, ClinicalTrials.gov; 2012. http:\/\/www.clinicaltrials.gov (Accessed 12 Apr 2013)."},{"issue":"9","key":"57_CR39","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/j.1464-5491.2010.03020.x","volume":"27","author":"RE Ratner","year":"2010","unstructured":"Ratner RE, Rosenstock J, Boka G, et al. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med. 2010;27(9):1024\u201332.","journal-title":"Diabet Med"},{"key":"57_CR40","unstructured":"Raccah D, Miossec P, Esposito V, et al. Efficacy and safety of lixisenatide in elderly (\u226565\u00a0years) and very elderly (\u226575\u00a0years) patients with type 2 diabetes: an analysis from the GetGoal Phase 3 programme [abstract no. 815]. Diabetologia. 2012;55 Suppl.1:S336."},{"key":"57_CR41","unstructured":"Bolli G, Munteanu M, Dotsenko S, et al. Long-term (up to 2\u00a0years) safety of lixisenatide once daily vs placebo in T2DM insufficiently controlled on metformin (GetGoal-F1) [abstract no. O-0595]. 21st World Congress of the International Diabetes Federation, Dubai; 4\u20138 Dec 2011."},{"key":"57_CR42","unstructured":"Sanofi. Lyxumia\u00ae is first diabetes therapy of its class approved for use combination with basal insulin; 2013. http:\/\/en.sanofi.com\/Images\/33261_20130628_LYXUMIA_en.pdf (Accessed 2 Jul 2013)."},{"key":"57_CR43","unstructured":"Sanofi. Sanofi New Drug Application for lixisenatide accepted for review by FDA; 2013. http:\/\/en.sanofi.com\/Images\/31904_20130219_LIXISENATIDE_en.pdf (Accessed 30 Apr 2013)."},{"issue":"8","key":"57_CR44","doi-asserted-by":"crossref","first-page":"e42551","DOI":"10.1371\/journal.pone.0042551","volume":"7","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Hu G, Yuan Z, et al. Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS ONE. 2012;7(8):e42551.","journal-title":"PLoS ONE"},{"key":"57_CR45","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1475-2840-8-23","volume":"8","author":"K Node","year":"2009","unstructured":"Node K, Inoue T. Postprandial hyperglycaemia as an etiological factor in vascular failure. Cardiovasc Diabetol. 2009;8:23.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"57_CR46","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2337\/diacare.26.3.881","volume":"26","author":"L Monnier","year":"2003","unstructured":"Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycaemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26(3):881\u20135.","journal-title":"Diabetes Care"},{"issue":"12","key":"57_CR47","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1007\/s001250100020","volume":"44","author":"E Bonora","year":"2001","unstructured":"Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. Diabetologia. 2001;44(12):2107\u201314.","journal-title":"Diabetologia"},{"key":"57_CR48","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatments and risk of complications in patients with type 2 diabetes. Lancet. 1998;352:837\u201353.","journal-title":"Lancet"},{"issue":"11","key":"57_CR49","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","volume":"52","author":"FM Turnbull","year":"2009","unstructured":"Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52(11):2288\u201398.","journal-title":"Diabetologia"},{"issue":"9677","key":"57_CR50","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","volume":"373","author":"KK Ray","year":"2009","unstructured":"Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373(9677):1765\u201372.","journal-title":"Lancet"},{"issue":"6","key":"57_CR51","doi-asserted-by":"crossref","first-page":"394","DOI":"10.7326\/0003-4819-151-6-200909150-00137","volume":"151","author":"TN Kelly","year":"2009","unstructured":"Kelly TN, Bazzano LA, Fonseca VA, et al. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med. 2009;151(6):394\u2013403.","journal-title":"Ann Intern Med"},{"issue":"15","key":"57_CR52","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577\u201389.","journal-title":"N Engl J Med"},{"issue":"6","key":"57_CR53","doi-asserted-by":"crossref","first-page":"421","DOI":"10.7326\/0003-4819-141-6-200409210-00007","volume":"141","author":"E Selvin","year":"2004","unstructured":"Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141(6):421\u201331.","journal-title":"Ann Intern Med"},{"key":"57_CR54","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2009.12.004","volume":"123","author":"M Stolar","year":"2010","unstructured":"Stolar M. Glycemic control and complications in type 2 diabetes mellitus. Am J Med. 2010;123:S3\u201311.","journal-title":"Am J Med"},{"issue":"3","key":"57_CR55","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1742-1241.2009.02227.x","volume":"64","author":"S Prato Del","year":"2010","unstructured":"Del Prato S, LaSalle J, Matthaei S, et al. Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management. Int J Clin Pract. 2010;64(3):295\u2013304.","journal-title":"Int J Clin Pract"},{"issue":"2","key":"57_CR56","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2337\/dc06-1612","volume":"30","author":"L Monnier","year":"2007","unstructured":"Monnier L, Colette C, Dunseath GJ, et al. The loss of prandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care. 2007;30(2):263\u20139.","journal-title":"Diabetes Care"},{"issue":"12","key":"57_CR57","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.2337\/dc11-0632","volume":"34","author":"M Riddle","year":"2011","unstructured":"Riddle M, Umpierrez G, DiGenio A, et al. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care. 2011;34(12):2508\u201314.","journal-title":"Diabetes Care"},{"key":"57_CR58","unstructured":"International Diabetes Foundation Clinical Guidelines Task Force. Global Guideline for type 2 diabetes; 2012. http:\/\/www.idf.org\/sites\/default\/files\/IDF-Guideline-for-Type-2-Diabetes.pdf (Accessed 8 May 2013)."},{"issue":"3","key":"57_CR59","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1742-1241.2010.02544.x","volume":"65","author":"CJ Bailey","year":"2011","unstructured":"Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract. 2011;65(3):314\u201322.","journal-title":"Int J Clin Pract"},{"key":"57_CR60","unstructured":"European Medicines Agency. Forxiga: summary of product characteristics; 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002322\/WC500136026.pdf (Accessed 10 May 2013)."},{"key":"57_CR61","unstructured":"Janssen Pharmaceuticals Inc. Invokana\u2122: US prescribing information. 2013. http:\/\/www.invokanahcp.com\/prescribing-information.pdf (Accessed 10 May 2013)."},{"key":"57_CR62","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0140-6736(11)60207-9","volume":"378","author":"AA Tahrani","year":"2011","unstructured":"Tahrani AA, Bailey CJ, Del Prato S, et al. Management of type 2 diabetes: new and future developments in the treatment. Lancet. 2011;378:182\u201397.","journal-title":"Lancet"},{"key":"57_CR63","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/0091270011400604","volume":"52","author":"RK Ghosh","year":"2012","unstructured":"Ghosh RK, Ghosh SM, Chawla S, et al. SGLT2 inhibitors: a new emerging class in the treatment of type 2 diabetes mellitus. J Clin Pharmacol. 2012;52:457\u201363.","journal-title":"J Clin Pharmacol"},{"key":"57_CR64","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1463-1326.2011.01511.x","volume":"14","author":"RA DeFronzo","year":"2012","unstructured":"DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metabol. 2012;14:5\u201314.","journal-title":"Diabetes Obes Metabol"},{"key":"57_CR65","doi-asserted-by":"crossref","unstructured":"Hirshberg B, Raz I. Impact of the US Food and Drug Administration cardiovascular assessment requirements on the drug development of novel antidiabetes drugs. Diabetes Care. 2011;34 Suppl.2:S101\u20136.","DOI":"10.2337\/dc11-s202"},{"key":"57_CR66","unstructured":"Sanofi. Evaluation of cardiovascular outcomes in patients with type 2 diabetes after acute coronary syndrome during treatment with AVE0010 (lixisenatide) (ELIXA) [ClinicalTrials.gov identifier NCT01147250]. US National Institutes of Health, ClinicalTrials.gov; 2013. http:\/\/www.clinicaltrials.gov (Accessed 9 May 2013)."},{"issue":"7","key":"57_CR67","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","volume":"173","author":"S Singh","year":"2013","unstructured":"Singh S, Chang H-Y, Richards TM, et al. Glucagon like peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus. JAMA Intern Med. 2013;173(7):534\u20139.","journal-title":"JAMA Intern Med"},{"key":"57_CR68","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.2337\/db12-1686","volume":"62","author":"AE Butler","year":"2013","unstructured":"Butler AE, Campbell-Thompson M, Gurlo T, et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013;62:2595\u2013604.","journal-title":"Diabetes"},{"key":"57_CR69","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","volume":"141","author":"M Elashoff","year":"2011","unstructured":"Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141:150\u20136.","journal-title":"Gastroenterology"},{"key":"57_CR70","author":"MA Nauck","year":"2013","unstructured":"Nauck MA. A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes Care. 2013. doi: 10.2337\/dc12-2504 .","journal-title":"Diabetes Care"},{"key":"57_CR71","unstructured":"European Medicines Agency. European Medcines Agency investigates findings on pancreatic risks with GLP-1-based therapies for type 2 diabetes; 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2013\/03\/WC500140866.pdf (Accessed 19 Jun 2013)."},{"key":"57_CR72","unstructured":"US Food and Drug Administration. FDA drug safety communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes; 2013. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm343187.htm (Accessed 19 Jun 2013)."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-013-0057-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-013-0057-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-013-0057-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T19:28:45Z","timestamp":1559503725000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-013-0057-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,6]]},"references-count":72,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["57"],"URL":"https:\/\/doi.org\/10.1007\/s40259-013-0057-y","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,6]]}}}